Understanding & Managing MASLD and MASH
Clear, hype-free guidance on Metabolic Dysfunction-Associated Steatotic Liver Disease (formerly NAFLD) and Steatohepatitis (formerly NASH) — from newly diagnosed basics and 2026 FDA-approved treatments to Mediterranean eating, noninvasive testing, and cirrhosis care.

If you just heard the letters MASLD or MASH — or if your chart still says NAFLD, NASH, or 'fatty liver' — take a slow breath. When a surgeon showed me a photo of my own scarred liver back in 2010 and told me medicine had nothing to offer, I felt like I'd been handed a sentence with no map. He was wrong about 'nothing to offer' then, and it's even less true today.
We built this pathway on SteatoticLiver.org so you don't have to bounce between outdated 'non-alcoholic' terminology and medical jargon. Everything here is organized around one practical goal: helping you find out your actual fibrosis stage, calm liver inflammation with sustainable food and modern therapies, and protect your future.
Why NAFLD Became MASLD & NASH Became MASH
- Steatotic Liver Disease (SLD) is now the umbrella term for excess fat buildup (≥5%) in liver cells.
- MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) replaces NAFLD — pointing directly to insulin resistance, blood sugar, weight, lipids, and blood pressure.
- MASH (Metabolic Dysfunction-Associated Steatohepatitis) replaces NASH — the inflammatory form that can build scar tissue (fibrosis).
- Over 98% of patients previously diagnosed with NAFLD meet MASLD criteria — your prior scan history still applies.
Three Truths Every Liver Patient Should Hear Early
- Normal blood enzymes don't clear you: Up to half of people with MASLD have normal ALT/AST. Ask for a FIB-4 score and stiffness scan.
- The liver wants to heal: Like skin fading an old cut, liver tissue can clear excess fat and shrink F1–F3 scarring when daily inflammation stops.
- We finally have real tools: Alongside Mediterranean nutrition and exercise, FDA-approved MASH medications (Rezdiffra and Wegovy/semaglutide) now treat at-risk F2–F3 MASH without requiring a biopsy.
How to Use This 37-Page Library Based on Your Situation
Nobody sits down on a Tuesday night wanting to read thirty-seven medical guides from cover to cover. After fifteen years of talking with newly diagnosed folks, panicked spouses, and fellow cirrhosis veterans, I know your real question tonight is much simpler: Where do I stand right now, and what do I actually need to do this month? Use the table below to skip straight to the pages built for your exact starting point, then come back for the deeper nutrition and liver biology guides once you catch your breath.
| Your Current Situation | Your Immediate Clinical Priority | Where to Start in This Library |
|---|---|---|
| 1. Just Diagnosed ("My scan or doctor mentioned liver fat or MASLD") | Don't stop at "watch what you eat." Find out whether you have simple fat storage (F0–F1) or hidden scar tissue (F2–F4) by calculating FIB-4 and asking about a painless stiffness scan. | Wish I Had Known • What Is MASLD? • Day-One Food Swaps |
| 2. Normal Liver Labs With Type 2 Diabetes or Prediabetes | Roughly 2 in 3 adults with Type 2 diabetes carry MASLD, and up to half have normal ALT and AST blood tests. Current diabetes guidelines call for proactive FIB-4 fibrosis screening even when liver enzymes look completely normal. | Am I at Risk? • Live FIB-4 Calculator • ADA Screening Guidance |
| 3. Active F2–F3 "At-Risk MASH" (FibroScan ~8–15 kPa, ELF 9.2–10.5, or biopsy F2–F3) | You sit inside the golden window where halting inflammation prevents cirrhosis altogether. Combine anti-inflammatory Mediterranean eating and strength work with a hepatology conversation about FDA-approved MASH therapies. | What Is MASH? • FDA-Approved Meds • Co-Pay Financial Help |
| 4. Compensated F4 Cirrhosis (No fluid buildup, bleeding, or confusion) | Keep your liver quiet and compensated: calendar every-6-month ultrasound + AFP liver cancer checks, protect muscle mass with adequate protein, watch portal pressure (platelets/varices), and explore dedicated F4 clinical trials. | MASH Cirrhosis Guide • Sodium & Protein Balance • F4 Drug Pipeline |
| 5. Family Member or Caregiver (Supporting a loved one with advanced disease) | Bring a notebook to appointments, organize medication lists, learn the early sleep-reversal and confusion signs of Hepatic Encephalopathy (HE), and understand MELD 3.0 and transplant center options early. | Caregiver & HE Kit • ESLD & MELD 3.0 • Transplant Prep Guide |

The 2023 Delphi SLD Umbrella: How Every Diagnosis Fits Together
In June 2023, more than seventy medical societies and patient organizations across fifty-six countries published a joint Delphi consensus updating forty years of liver terminology. Why does that matter when you're reading old medical records or hospital discharge papers? Because many clinic templates still print legacy terms like NAFLD (renamed MASLD) or NASH (renamed MASH), while hepatologists and clinical trials now group all fat-accumulating liver conditions under one clear umbrella: Steatotic Liver Disease (SLD).
Even more helpful, the updated framework finally stopped pretending people live in neat all-or-nothing boxes. In the real world, someone can have high blood sugar and belly fat and drink two glasses of wine every evening, or take a heart medication that pushes fat into liver cells. Here is how clinicians map the entire SLD family today:
| 2023 SLD Category | Historical / Chart Term | Defining Clinical Criteria | Why the Distinction Matters for Care |
|---|---|---|---|
| MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease | Formerly NAFLD (Non-Alcoholic Fatty Liver Disease) | Steatosis in ≥5% of liver cells + at least 1 of 5 cardiometabolic risk factors + low alcohol (<20 g/day women; <30 g/day men). | Points treatment directly at insulin resistance, nutrition, muscle movement, and heart protection (Read MASLD Guide). |
| MASH Metabolic Dysfunction-Associated Steatohepatitis | Formerly NASH (Non-Alcoholic Steatohepatitis) | MASLD plus active lobular inflammation and hepatocyte ballooning, with or without collagen fibrosis (F1–F4). | Identifies active tissue injury that drives scar buildup and qualifies F2–F3 patients for FDA-approved MASH drugs (Read MASH Guide). |
| MetALD Metabolic + Alcohol-Related Liver Disease | No prior category (Previously excluded from NAFLD trials) | Steatosis + ≥1 cardiometabolic trait + moderate weekly alcohol (140–350 g/wk women; 210–420 g/wk men — roughly 10–25 standard drinks/wk). | Metabolic stress and alcohol multiply fibrosis risk faster together than either one alone (Explore MetALD Hub). |
| ALD Alcohol-Associated Liver Disease | Alcoholic Fatty Liver / Alcoholic Steatohepatitis | Steatosis driven predominantly by higher alcohol intake (>350 g/wk women; >420 g/wk men) or binge patterns, with or without metabolic traits. | Sustained sobriety rapidly quiets liver inflammation alongside nutritional rebuilding (Visit Sober Livers). |
| Specific-Etiology SLD Drug, Toxin, Viral, or Genetic | Secondary Fatty Liver | Triggered by steatogenic drugs (amiodarone, methotrexate, tamoxifen, chronic steroids), HCV genotype 3, Wilson disease, LAL-D, or lipodystrophy. | Fixing or substituting the specific medication, toxin, or inherited enzyme defect treats the root driver (Toxins & Meds). |
| Cryptogenic SLD | Cryptogenic Fatty Liver / Cirrhosis | Hepatic steatosis with zero cardiometabolic traits, low/no alcohol, and negative secondary/genetic testing. | Prompts specialist evaluation for subtle genetic variants or burned-out prior MASH (Cryptogenic SLD). |
Explore All 5 Sections of the MASLD & MASH Pathway
Plain-language roadmap from newly diagnosed questions and the 5 cardiometabolic risk factors to MASH inflammation, RUQ liver pain, prognosis, and liver biology.
2026 guide to FDA-approved MASH therapies (Rezdiffra and Wegovy/GLP-1s), next-generation drug trials, co-pay assistance foundations, and noninvasive FibroScan/FIB-4 testing.
Evidence-based Mediterranean eating without fads or guilt: simple day-one food swaps, popular diet comparisons, fructose, coffee, olive oil, omega-3s, sodium, and supplement safety.
Calm, practical guidance for compensated and decompensated MASH cirrhosis, MELD 3.0, comparing transplant centers, living liver donation, and caregiving for Hepatic Encephalopathy.
Real patient journeys from diagnosis to recovery, curated MASH video explainers, lessons from community elastography screening, and our complete Spanish-language MASLD/MASH guide.

Turning Personal Knowledge Into Better Care for Everyone
One lesson we've learned the hard way is that medical systems don't fix blind spots out of pure goodwill — they move when informed patients walk into exam rooms asking sharp questions and when patient organizations publish hard numbers they can't ignore. Alongside these thirty-seven clinical guides, you can run your own numbers in our Noninvasive Diagnostics & Calculator Hub, search vetted partner support through The Wellness League, and add your anonymous voice to our annual State of Steatotic Liver Care Survey so fewer families have to discover liver scarring by accident.
Common Questions Patients & Families Ask
My medical records still say 'NAFLD' or 'NASH' — is MASLD or MASH a different disease?
No — it is the exact same liver biology with a clearer, updated name. In June 2023, over 70 global medical societies renamed NAFLD to MASLD and NASH to MASH so diagnoses reflect metabolic root causes rather than defining you by alcohol. Large registry studies confirm over 98% overlap between historical NAFLD cohorts and MASLD, so all of your past blood work, scans, and insurance history carry straight forward.
Do I have to undergo a surgical liver biopsy to get staged or treated today?
Almost never for routine care. Modern hepatology uses a painless two-step noninvasive pathway: first, a free blood-panel calculation called FIB-4 (using Age, AST, ALT, and Platelets), followed when needed by sound-wave elastography (such as FibroScan, Shear Wave Elastography, or Velacur) or blood fibrosis panels like ELF. Even FDA-approved MASH medications for Stages F2–F3 are prescribed using noninvasive test thresholds rather than biopsy.
Can MASLD and early MASH genuinely reverse, or can we only slow them down?
Both liver fat and early-to-moderate collagen scarring can genuinely reverse. Excess fat inside hepatocytes often drops measurably within 4 to 12 weeks of cutting sugary drinks and shifting toward Mediterranean whole foods. Once daily cellular inflammation quiets down, scar-producing stellate cells stand down and natural matrix enzymes remodel F1–F3 fibrosis over 1 to 3+ years of steady care.
What if I have metabolic risk factors and also drink wine, beer, or spirits most weeks?
You aren't alone, and the 2023 Steatotic Liver Disease umbrella created a dedicated category called MetALD specifically for people who have cardiometabolic traits plus moderate weekly alcohol intake (roughly 140–350 g/week for women or 210–420 g/week for men). Because alcohol and insulin resistance multiply scar speed inside the same liver cells, trimming or pausing alcohol gives your liver immediate breathing room.
Where to Go Deeper: Related Guides & Trusted Resources
Plug in your Age, AST, ALT, and Platelet Count from any routine lab report to screen for hidden fibrosis in 30 seconds.
Avoid the two biggest diagnostic blind spots, build a 1-page liver tracker, and bring 5 sharp questions to your doctor.
Plain-spoken breakdown of Phase 3 biopsy trial results, noninvasive F2–F3 eligibility, and statin heart protection.
Share your diagnostic experience anonymously to help us press health systems and insurers for earlier liver screening.
Read the landmark international consensus replacing legacy NAFLD and NASH with MASLD, MASH, and MetALD.
National Institute of Diabetes and Digestive and Kidney Diseases patient overview of steatotic liver disease.